AbbVie Reaffirms 2026 Guidance After Closing $10.9 Billion Apogee Acquisition
AbbVie completed its acquisition of Apogee Therapeutics for $10.9 billion in cash, adding two late-stage immunology assets to its pipeline
Evidence Sheet: UnitedHealth Group (UNH)
The standing BullScope yardsticks for UnitedHealth Group, computed from official filings and refreshed with each new edition.
A 95% Gross Margin and a P/S Below Its Own Median: PTC Therapeutics’ Profitability Flip Is Real, and the Valuation Gap Raises Questions
In one breath PTC Therapeutics spent the better part of a decade burning cash on a pipeline that mostly disappointed....
UnitedHealth’s Numbers Are Healing Faster Than Its Stock Admits
A year ago, UnitedHealth was paying out nearly ninety cents of every premium dollar in medical claims, a pace that...
Evidence Sheet: Moderna (MRNA)
The standing BullScope yardsticks for Moderna, computed from official filings and refreshed with each new edition.
A $2.4 Billion Question: What Sarepta’s Filed Numbers Actually Say
The gist of it Sarepta's filed numbers tell a story of a company that briefly turned profitable in 2024, then...
Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work
Before anything else Moderna's filed revenue has fallen every year since 2022, and the company is burning through roughly $600...
Moderna raises $2.6 billion in zero-coupon convertibles as revenue collapses, betting oncology turnaround
Moderna priced a $2.6 billion offering of convertible senior notes due 2032 on August 28, 2026, upsized from an initially...
Caterpillar renews three-year credit facility with unchanged $4 billion commitment as borrowing costs shift to SOFR
Caterpillar Inc. has executed a fifth amendment to its revolving credit agreement, dated August 27, 2026, maintaining a three-year facility
Evidence Sheet: Organon & (OGN)
The standing BullScope yardsticks for Organon &, computed from official filings and refreshed with each new edition.
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.